Ticker brief · 2026-07-03
TMDX TRANSMEDICS GROUP INC
Bulls fade Stifel as flight data strengthens
Consumer, Non-cyclical · Healthcare-Products
Lean: bullishlast close
$68.86
1 day
+1.5%
14 days
-12.6%
mkt cap
$2.4B
signals 14d
80
authors 14d
27
The tape skews bullish, with credible longs treating the Stifel-driven selloff as an add point while flight and OPTN data argue for a Q2 revenue beat. The late-week shift was from defending against dry-run concerns to citing record June and Q2 flight activity, including revenue expectations of 190-195m above consensus. Trade structure is mostly long equity and add-on-dip behavior, with limited bearish follow-through outside Stifel-linked estimate risk.
BULL CAMP
Bulls argue the Stifel dry-run concern is either refuted or immaterial, while record flight activity and OPTN DCD growth point to a stronger Q2 than consensus. The highest-conviction accounts are adding or already long, though several have cold recent trader scores.
Key voices@JonahLuptonMEDIUM-HIGHA+1.14@nataninvestingMEDIUM-HIGHB-0.89@ripster47HIGHC-0.91@mathlonningMEDIUMA-1.85@KabraxFXMEDIUMB+1.84
“Flight and OPTN data support 190-195m revenue, above consensus.”— @mathlonning · tweet ↗
BEAR / SKEPTIC
Bears are concentrated around Stifel-linked concerns that Q2 revenue expectations may be too aggressive, dry-run commentary could matter, and EPS reset risk remains. There is also a secondary concern that more flights may not translate into proportional revenue if CHOPS mix rises.
Key voices“Stifel Hold note flags caution on Q2 beat and EPS reset risk.”— @AIStockSavvy · tweet ↗
Hypotheses8direction · basis · magnitude · supporters — NEW = first seen this week
▲Stifel dry-run concerns are overstated or refuted, leaving guidance achievable and the selloff as an overreaction.
@mathlonningMEDIUMA-1.857s · insight@JonahLuptonMEDIUM-HIGHA+1.141s · insight@KabraxFXMEDIUMB+1.842s@ripster47HIGHC-0.911s
▲Record flight activity and OPTN DCD growth imply a strong Q2 revenue beat versus consensus.
@mathlonningMEDIUMA-1.855s · insight@JonahLuptonMEDIUM-HIGHA+1.141s · insight@KabraxFXMEDIUMB+1.841s@AIStockSavvyMEDIUMC+0.051s
▼Stifel-linked caution says Q2 revenue estimates may be too aggressive and EPS reset risk remains.
@AIStockSavvyMEDIUMC+0.051s@ABBONewsMEDIUMC1s@dywidendowoplLOW-MEDIUMC+1.451s@mathlonningMEDIUMA-1.851s · insight
▲The post-selloff setup offers attractive risk/reward, prompting multiple investors to add or bid shares.
@nataninvestingMEDIUM-HIGHB-0.892s@ripster47HIGHC-0.912s@mathlonningMEDIUMA-1.851s · insight@PharmdcaMEDIUM-HIGHC-1.501s@UltimateTrad8rLOW-MEDIUMC+1.371s@growthrapidlyMEDIUMC-3.001s+2 more
▲Healthcare and medtech rotation provide a supportive backdrop for TMDX exposure.
@mathlonningMEDIUMA-1.851s · insight@AlphaOwlTradingLOW-MEDIUMC+1.701s@BourbonCapMEDIUM-HIGHB-2.501s · insight
▲TMDX has a durable organ-logistics aviation moat supporting long-term growth and valuation upside.
▼Increased flights may reflect CHOPS activity with lower revenue per flight, limiting revenue upside.
@mathlonningMEDIUMA-1.851s · insight
▼TMDX valuation, communication, and board or IR execution create opportunity-cost and de-rating risk.
@mathlonningMEDIUMA-1.853s · insight@SixSigmaCapitalMEDIUM-HIGHB-0.481s · insight
Direct calls5authors taking explicit directional positions
@mathlonningMEDIUMA-1.85
Got to add TMDX after this
@nataninvestingMEDIUM-HIGHB-0.89
Bought more TMDX.
@ripster47HIGHC-0.91
Added TMDX today
@mind1nvestorMEDIUMC+1.86
Buy order set near buy zone; long-term target $300+
@PharmdcaMEDIUM-HIGHC-1.50
Bought TMDX shares.
Sellside activity4
Stifel reiterateReiterates Hold with caution on Q2 beat and EPS reset risk.
Stifel target PT 80Reiterates Hold and 80 PT, noting Q2 revenue estimate may be too aggressive.
Stifel pt_cut PT 185 (from 195)Estimate cut from 195 to 185 viewed by bulls as an overreaction while guidance remains achievable.
TD Cowen reiterate PT 120Reiterates Buy and $120 target, citing transplant volumes and flight activity.
News / data points5discrete events + data quoted by authors
@JonahLuptonMEDIUM-HIGHA+1.14
TMDX refutes Stifel dry-run concern while June flights are best ever, +33% YoY.
@KabraxFXMEDIUMB+1.84
Q2 ended with record flights, up 12.1% QoQ.
@mathlonningMEDIUMA-1.85
Flight and OPTN data point to 190-195m revenue above consensus.
@AIStockSavvyMEDIUMC+0.05
TD Cowen reiterates Buy and $120 target on transplant volumes and flight activity.
@ABBONewsMEDIUMC
Stifel reiterates Hold and 80 PT, saying Q2 revenue estimates may be aggressive.
Position disclosures3skin in the game
@nataninvestingMEDIUM-HIGHB-0.89
Bought more TMDX and later disclosed 75% portfolio allocated to five tickers including holdings.
@ripster47HIGHC-0.91
Long TMDX, added shares, and says risk/reward is great here.
@ID_Research_MEDIUM-HIGHA-1.25
Duplicating position at $64 would be a top decision after recovery of half the drop.
Desk readconvergence assessment
The view is moderately converged bullish: most credible voices are either adding or defending the setup, and the late-week data emphasis shifted toward record flight activity rather than just rebutting Stifel. The main disagreement is whether flights convert into revenue and whether Stifel’s dry-run concern is real; the bearish camp is narrower and mostly relays sell-side caution, while several bullish anchors have negative trader_score_20, especially mathlonning, ripster47, and nataninvesting. A confirmed revenue miss, weaker revenue per flight, or management silence around dry runs would break the bull convergence.
Tracked hypotheses — caliber-scored view · 2026-06-22
🟡 MEDIUM caliber (1)
📈 h4 bull · score 0.30
TMDX technicals are improving, with a gap-fill and weekly-close confirmation pointing toward the mid-90s to low-100s.
- Supporters (4): @mathlonning↗(MEDIUM,2p), @Blaine_Tarr↗(LOW-MED,1p), @ripster47↗(HIGH,1p), @Tautilas↗(LOW-MED,3p)
- Signals: 6 · Max author share: 0.43 · Novelty: building
- ⚠️ Concentration: 50% from @tautilas↗ LOW-MEDIUM cred
- Quote: "Resistance in the mid-80s could give way to a move into the 100s" — mathlonning
⚪ LOW caliber (1)
↔️ h7 neutral · score 0.00
Stifel’s Hold rating despite a higher target suggests a likely Q2 beat is not enough to resolve longer-term concerns.
- Supporters (0):
- Signals: 1 · Max author share: 0.00 · Novelty: stable
- ⚠️ Concentration: 100% from @aistocksavvy↗ MEDIUM cred
- Quote: "Stifel raised its target but kept Hold, seeing a likely Q2 beat with neutral long-term view" — AIStockSavvy
🔴 FLAGGED caliber (8)
📉 h9 bear · score 0.11
The prior EPS miss shows TMDX still carries execution risk despite improving activity data and bullish positioning.
- Supporters (1): @SixSigmaCapital↗(MEDIUM-,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: new
- ⚠️ Concentration: 100% from @sixsigmacapital↗ MEDIUM-HIGH cred
- Quote: "Last quarter’s EPS miss was a negative surprise investors still need to weigh" — SixSigmaCapital
📈 h6 bull · score 0.10
Long-term holders expect TMDX to compound at 25% or better annually over the next three years.
- Supporters (1): @nataninvesting↗(MEDIUM-,2p)
- Signals: 2 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @nataninvesting↗ MEDIUM-HIGH cred
- Quote: "Added to TMDX while expecting 25%+ compound annual growth over three years" — nataninvesting
📈 h1 bull · score 0.10
June flight activity is running far above seasonal norms and implies Q2 revenue ahead of Street estimates, potentially above $200 million.
- Supporters (2): @mathlonning↗(MEDIUM,8p), @JonahLupton↗(MEDIUM-,2p)
- Signals: 9 · Max author share: 0.80 · Novelty: stable
- ⚠️ Concentration: 78% from @mathlonning↗ MEDIUM cred
- Quote: "Flight data implies Q2 revenue is tracking above Street estimates" — JonahLupton
📈 h2 bull · score 0.07
The market overreacted to prior weakness, leaving room for TMDX to rerate if the current quarter confirms acceleration.
- Supporters (2): @mathlonning↗(MEDIUM,3p), @CaesarCapitalz↗(LOW-MED,1p)
- Signals: 4 · Max author share: 0.75 · Novelty: stable
- ⚠️ Concentration: 75% from @mathlonning↗ MEDIUM cred
- Quote: "Stock reaction was excessive if current-quarter revenue can still reach $200 million" — mathlonning
📉 h8 bear · score 0.06
The kidney-device program must remain on schedule or TMDX may miss longer-term strategic and financial goals.
- Supporters (1): @mathlonning↗(MEDIUM,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: new
- ⚠️ Concentration: 100% from @mathlonning↗ MEDIUM cred
- Quote: "Kidney device delays could make company goals harder to achieve" — mathlonning
📈 h3 bull · score 0.05
OCS kidney visibility on June 22 could validate pipeline progress and keep 2027 clinical trial timing on track.
- Supporters (1): @mathlonning↗(MEDIUM,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @mathlonning↗ MEDIUM cred
- Quote: "Early OCS kidney glimpse may indicate the program remains on track for 2027 trials" — mathlonning
📉 h10 bear · score 0.03
Macro and healthcare-sector pressure can still weigh on TMDX even when company-specific flight data is improving.
- Supporters (1): @mathlonning↗(MEDIUM,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @mathlonning↗ MEDIUM cred
- Quote: "Stock remains affected by multiple macro and sector risks" — mathlonning
📈 h5 bull · score 0.01
Unusual bullish options activity indicates near-term positioning support for continued upside in TMDX.
- Supporters (1): @OptionsFlowBoss↗(LOW-MED,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @optionsflowboss↗ LOW-MEDIUM cred
- Quote: "Unusual bullish options volume appeared among highlighted tickers" — OptionsFlowBoss
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-02 · now +0.25 (−1 bearish … +1 bullish)
Who spoke27
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @mathlonning | A | -1.85 | 32 | +0.30 |
| @nataninvesting | B | -0.89 | 6 | +0.44 |
| @JonahLupton | A | +1.14 | 6 | +0.57 |
| @ripster47 | C | -0.91 | 5 | +0.50 |
| @KabraxFX | B | +1.84 | 4 | +0.39 |
| @SixSigmaCapital | B | -0.48 | 3 | -0.05 |
| @EmmanuelInvest | C | -1.12 | 2 | +0.15 |
| @AIStockSavvy | C | +0.05 | 2 | +0.10 |
| @mind1nvestor | C | +1.86 | 2 | +0.55 |
| @MMatters22596 | C | +1.15 | 1 | +0.35 |
| @FIREDUpWealth | C | -1.24 | 1 | +0.00 |
| @MitchMartan98 | C | +1.40 | 1 | +0.40 |
| @BourbonInsider | C | -0.83 | 1 | +0.15 |
| @ID_Research_ | A | -1.25 | 1 | +0.75 |
| @ABBONews | C | · | 1 | -0.15 |
| @dywidendowopl | C | +1.45 | 1 | -0.20 |
| @JRamirezChacon1 | C | +1.67 | 1 | +0.25 |
| @MMMTwealth | A | +1.97 | 1 | +0.30 |
| @aflat0n | C | -1.99 | 1 | +0.25 |
| @SuEricGP | B | +0.42 | 1 | +0.15 |
| @AlphaOwlTrading | C | +1.70 | 1 | +0.25 |
| @BourbonCap | B | -2.50 | 1 | +0.30 |
| @Pharmdca | C | -1.50 | 1 | +0.75 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @growthrapidly | C | -3.00 | 1 | +0.25 |
Recent signals30of 80 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @mathlonning | -0.15 | Speculates increased flights may be tied to CHOPS with lower revenue per flight. | — | tweet ↗ |
| 2026-07-02 | @nataninvesting | +0.35 | Portfolio update discloses holdings, YTD returns, increased/decreased positions and allocation. | — | tweet ↗ |
| 2026-07-02 | @mind1nvestor | +0.55 | Profiles TMDX with Q1 revenue, FY guidance and organ-logistics aviation moat. | — | tweet ↗ |
| 2026-07-01 | @nataninvesting | +0.35 | Discloses 75% portfolio allocated to five tickers. | +1.5% | tweet ↗ |
| 2026-07-01 | @mathlonning | +0.15 | Raises question whether Europe operations can offset US transplant seasonality. | +1.5% | tweet ↗ |
| 2026-07-01 | @SixSigmaCapital | -0.15 | Says TMDX had gotten costly, mild valuation caution. | +1.5% | tweet ↗ |
| 2026-07-01 | @ripster47 | +0.40 | Says portfolio is going parabolic and hitting highs due to named longs. | +1.5% | tweet ↗ |
| 2026-07-01 | @KabraxFX | +0.15 | Defends TMDX regarding dry-run comments, but stance is limited. | +1.5% | tweet ↗ |
| 2026-07-01 | @ripster47 | +0.50 | References buying the dip earlier and now others chasing. | +1.5% | tweet ↗ |
| 2026-07-01 | @AIStockSavvy | +0.40 | TD Cowen reiterates Buy and $120 target, citing transplant volumes and flight activity. | +1.5% | tweet ↗ |
| 2026-07-01 | @KabraxFX | +0.20 | Says TMDX is supposedly refuting Stifel with other analysts. | +1.5% | tweet ↗ |
| 2026-07-01 | @mathlonning | +0.65 | Says TMDX will crush the quarter, a clear bullish earnings expectation without trade mechanics. | +1.5% | tweet ↗ |
| 2026-07-01 | @JonahLupton | +0.40 | Discloses fund positions, 6% NBIS add, and strong long-term bullishness. | +1.5% | tweet ↗ |
| 2026-07-01 | @KabraxFX | +0.55 | Reports TMDX ended Q2 with record flights, up 12.1% QoQ. | +1.5% | tweet ↗ |
| 2026-07-01 | @Ruby_investment | +0.20 | Comments on tenbagger potential and relative appeal of TMDX, RDW and ABCL. | +1.5% | tweet ↗ |
| 2026-06-30 | @mathlonning | +0.60 | Cites flight and OPTN data, expecting revenue of 190-195m above consensus. | +3.7% | tweet ↗ |
| 2026-06-30 | @mathlonning | -0.50 | Criticizes TMDX opportunity cost, communication, and board/IR leadership. | +3.7% | tweet ↗ |
| 2026-06-30 | @JonahLupton | +0.65 | Very bullish on HROW and other owned stocks based on targets, valuation, and execution upside. | +3.7% | tweet ↗ |
| 2026-06-30 | @ripster47 | +0.65 | States they are long TMDX and says risk/reward is great here. | +3.7% | tweet ↗ |
| 2026-06-30 | @UltimateTrad8r | +0.55 | Going to throw a bid on TMDX. — Author states intent to bid for TMDX. | +3.7% | tweet ↗ |
| 2026-06-30 | @growthrapidly | +0.25 | Buying or would consider buying these stocks at current levels. — Author lists stocks they are buying or would consider buying now, with disclosed positions. | +3.7% | tweet ↗ |
| 2026-06-29 | @mathlonning | +0.45 | Reports TMDX had the most flights in a month ever, with a day to go. | +2.3% | tweet ↗ |
| 2026-06-29 | @nataninvesting | +0.75 | Explicitly says bought more TMDX. | +2.3% | tweet ↗ |
| 2026-06-29 | @nataninvesting | +0.75 | Considering buying even more TMDX. — Forward add intent with valuation and growth thesis. | +2.3% | tweet ↗ |
| 2026-06-29 | @mathlonning | +0.15 | Constructive long-term vision but criticizes management communication and hit-piece vulnerability. | +2.3% | tweet ↗ |
| 2026-06-29 | @OptionsFlowBoss | +0.35 | Says TMDX should be a rolldown of a bullish RR and to check OI. | +2.3% | tweet ↗ |
| 2026-06-29 | @mathlonning | +0.00 | Expects analyst notes before TMDX earnings; awaits revenue estimates. | +2.3% | tweet ↗ |
| 2026-06-29 | @Pharmdca | +0.75 | Author says they bought TMDX shares. | +2.3% | tweet ↗ |
| 2026-06-28 | @mathlonning | +0.55 | Expect TMDX to regain some of last week's losses — Expects rebound after management rebuttal of Stifel comments and possible statement tomorrow. | +0.6% | tweet ↗ |
| 2026-06-28 | @BourbonCap | +0.30 | Says TMDX fits perfectly in a favorable list, but context is missing. | +0.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.